M
Mary-Jane Navarro
Researcher at University of Washington
Publications - 4
Citations - 540
Mary-Jane Navarro is an academic researcher from University of Washington. The author has contributed to research in topics: Signal peptide & Antibody. The author has an hindex of 4, co-authored 4 publications receiving 210 citations.
Papers
More filters
Journal ArticleDOI
SARS-CoV-2 immune evasion by the B.1.427/B.1.429 variant of concern.
Matthew McCallum,Jessica Bassi,Anna De Marco,Alexander Chen,Alexandra C. Walls,Julia di Iulio,M. Alejandra Tortorici,Mary-Jane Navarro,Chiara Silacci-Fregni,Christian Saliba,Kaitlin R. Sprouse,Maria De Agostini,Dora Pinto,Katja Culap,Siro Bianchi,Stefano Jaconi,Elisabetta Cameroni,John E. Bowen,Sasha W Tilles,Matteo Samuele Pizzuto,Sonja Bernasconi Guastalla,Giovanni Bona,Alessandra Franzetti Pellanda,Christian Garzoni,Wesley C. Van Voorhis,Laura E. Rosen,Gyorgy Snell,Amalio Telenti,Herbert W. Virgin,Luca Piccoli,Davide Corti,David Veesler +31 more
TL;DR: In this paper, a novel variant of concern (VOC) named CAL.20C (B.1.427/B. 1.429), which was originally detected in California, carries spike glycoprotein mutations S13I in the signal peptide, W152C in the N-terminal domain (NTD), and L452R in the receptor-binding domain (RBD).
Posted ContentDOI
SARS-CoV-2 immune evasion by variant B.1.427/B.1.429
Matthew McCallum,Jessica Bassi,Anna De Marco,Alexander Chen,Alexandra C. Walls,Julia di Iulio,M. Alejandra Tortorici,Mary-Jane Navarro,Chiara Silacci-Fregni,Christian Saliba,Maria De Agostini,Dora Pinto,Katja Culap,Siro Bianchi,Stefano Jaconi,Elisabetta Cameroni,John E. Bowen,Sasha W Tiles,Matteo Samuele Pizzuto,Sonja Bernasconi Guastalla,Giovanni Bona,Alessandra Franzetti Pellanda,Christian Garzoni,Wesley C. Van Voorhis,Laura E. Rosen,G. Snell,Amalio Telenti,Herbert W. Virgin,Luca Piccoli,Davide Corti,David Veesler +30 more
TL;DR: In this article, neutralizing antibody responses to SARS-CoV-2 infection or to the prototypic Wuhan-1 isolate-based vaccines will be impacted by the three B.1.20C (B.1,1.1.,1.429) mutations: S13I, W152C and L452R, which reduced neutralizing activity of 14 out of 35 RBD-specific monoclonal antibodies.
Journal ArticleDOI
Elicitation of broadly protective sarbecovirus immunity by receptor-binding domain nanoparticle vaccines.
Alexandra C. Walls,Marcos C. Miranda,Alexandra Schäfer,Minh N. Pham,Allison J. Greaney,Allison J. Greaney,Prabhu S. Arunachalam,Mary-Jane Navarro,M. Alejandra Tortorici,M. Alejandra Tortorici,Kenneth A. Rogers,Megan A. O'Connor,Lisa Shirreff,Douglas E. Ferrell,John E. Bowen,Natalie Brunette,Elizabeth Kepl,Samantha K Zepeda,Tyler N. Starr,Ching-Lin Hsieh,Brooke Fiala,Samuel Wrenn,Deleah Pettie,Claire Sydeman,Kaitlin R. Sprouse,Max Johnson,Alyssa Blackstone,Rashmi Ravichandran,Cassandra Ogohara,Lauren Carter,Sasha W Tilles,Rino Rappuoli,Sarah R. Leist,David R. Martinez,Matthew Clark,Roland Tisch,Derek T. O'Hagan,Robbert van der Most,Wesley C. Van Voorhis,Davide Corti,Jason S. McLellan,Harry Kleanthous,Timothy P. Sheahan,Kelly D. Smith,Deborah H. Fuller,Francois Villinger,Jesse D. Bloom,Jesse D. Bloom,Bali Pulendran,Ralph S. Baric,Neil P. King,David Veesler +51 more
TL;DR: In this paper, a clinical stage multivalent SARS-CoV-2 spike receptor-binding domain nanoparticle (RBD-NP) vaccine was used to protect mice from SARS CoV 2 challenge after a single immunization.
Posted ContentDOI
Elicitation of broadly protective sarbecovirus immunity by receptor-binding domain nanoparticle vaccines
Alexandra C. Walls,Marcos C. Miranda,Minh N. Pham,Alexandra Schäfer,Allison J. Greaney,Allison J. Greaney,Prabhu S. Arunachalam,Mary-Jane Navarro,M. Alejandra Tortorici,M. Alejandra Tortorici,Kenneth A. Rogers,Megan A. O'Connor,Lisa Shireff,Douglas E. Ferrell,Natalie Brunette,Elizabeth Kepl,John E. Bowen,Samantha K Zepeda,Tyler N. Starr,Ching-Lin Hsieh,Brooke Fiala,Samuel Wrenn,Deleah Pettie,Claire Sydeman,Max Johnson,Alyssa Blackstone,Rashmi Ravichandran,Cassandra Ogohara,Lauren Carter,Sasha W Tilles,Rino Rappuoli,Derek T. O'Hagan,Robbert van der Most,Wesley C. Van Voorhis,Jason S. McLellan,Harry Kleanthous,Timothy P. Sheahan,Deborah H. Fuller,Francois Villinger,Jesse D. Bloom,Jesse D. Bloom,Bali Pulendran,Ralph S. Baric,Neil P. King,David Veesler +44 more
TL;DR: This study provides proof of principle that sarbecovirus RBD-NPs induce heterotypic protection and enables advancement of broadly protective sarBecovirus vaccines to the clinic.